PACIRA BIOSCIENCES, INC.

(PCRX)
  Report
Delayed Nasdaq  -  05/19 04:00:00 pm EDT
63.04 USD   +2.65%
05/12Pacira BioSciences Posts Higher Exparel, Lower Iovera Sales in April
MT
05/12Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45.8 Million for April 2022
GL
05/10Pacira BioSciences to Present at Two Healthcare Conferences in May
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pacira BioSciences Logs Higher Exparel, Iovera Sales in November

12/07/2021 | 08:45am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
PACIRA BIOSCIENCES, INC. 2.65% 63.04 Delayed Quote.4.77%
All news about PACIRA BIOSCIENCES, INC.
05/12Pacira BioSciences Posts Higher Exparel, Lower Iovera Sales in April
MT
05/12Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45..
GL
05/10Pacira BioSciences to Present at Two Healthcare Conferences in May
GL
05/10Pacira BioSciences to Present at Two Healthcare Conferences in May
AQ
05/10Genascence Corporation announced that it expects to receive funding from Pacira BioScie..
CI
05/05RBC Capital Adjusts Pacira BioSciences' Price Target to $81 From $85, Maintains Outperf..
MT
05/04PACIRA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
05/04Pacira BioSciences Q1 Non-GAAP EPS, Revenue Higher
MT
05/04TRANSCRIPT : Pacira BioSciences, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04PACIRA : Q1 Earnings Snapshot
AQ
More news
Analyst Recommendations on PACIRA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 707 M - -
Net income 2022 90,4 M - -
Net Debt 2022 25,0 M - -
P/E ratio 2022 33,1x
Yield 2022 -
Capitalization 2 790 M 2 790 M -
EV / Sales 2022 3,98x
EV / Sales 2023 3,35x
Nbr of Employees 697
Free-Float 98,9%
Chart PACIRA BIOSCIENCES, INC.
Duration : Period :
Pacira BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PACIRA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 61,41 $
Average target price 80,46 $
Spread / Average Target 31,0%
EPS Revisions
Managers and Directors
David M. Stack Chairman & Chief Executive Officer
Charles A. Reinhart Chief Financial Officer
Roy Winston Chief Medical Officer
Charles Anthony Laranjeira Senior Vice President-Technical Operations
Jonathan Slonin Chief Clinical Officer
Sector and Competitors
1st jan.Capi. (M$)
PACIRA BIOSCIENCES, INC.2.06%2 790
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329